Skip to main content

Table 1 Patient demographic and clinical data

From: Normalization of prostate specific antigen in patients treated with intensity modulated radiotherapy for clinically localized prostate cancer

Variable

Value

Age (n = 121)*

69.5 ± 0.7

NAAD

56/83 (67.5%)

Time of hormonal treatment (mon; n = 52)*

9.3 ± 1.1

Gleason Score (n = 132)

6 (5 - 10)

Pre-PSA (ng/mL)*

9.5 ± 0.6

Unilateral disease

65/117 (55.6%)

IMRT Boost

31/130 (23.9%)

Tumor stage

 

   T1c

100/130 (76.9%)

   T2

5/130 (3.9%)

   T2a

13/130 (10.0%)

   T2b

4/130 (3.1%)

   T2c

2/130 (1.5%)

   T3

3/130 (2.3%)

   T3a

2/130 (1.5%)

   T3b

1/130 (0.8%)

  1. Abbreviation: NAAD = Neoadjuvant androgen deprivation therapy; PSA = Prostate specific antigen; IMRT = intensity modulated radiation therapy
  2. * mean ± SEM
  3. † median (range in parentheses)